{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:37:38Z","timestamp":1791488258014,"version":"4.3.4"},"reference-count":69,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Increased activity of B lymphocytes underpins many autoimmune conditions. A key component of the humoral immune response involves the A PRoliferation-Inducing Ligand (APRIL) and B-cell-activating factor (BAFF) system. These proteins are responsible for the activation, maturation, and survival of B lymphocytes, playing a pivotal role in autoimmunity. Therefore, targeting the BAFF\/APRIL system proves promising for the treatment of various autoimmune diseases. Meticulous research into pathomechanisms of lupus nephritis (LN) has enabled the introduction of biological treatments targeting the BAFF-mediated pathway, significantly improving prognosis. In certain types of glomerulonephritis (GN), increased levels of the BAFF\/APRIL system might be associated with higher proteinuria, elevated serum creatinine, but also with specific histopathological features. This indicates that biological therapies currently available could be repurposed for conditions where increased activation of B lymphocytes plays a critical role in the disease's pathophysiology. Understanding the mechanisms underlying autoimmune diseases will facilitate the adaptation of novel drugs for orphan diseases. That is why the use of chimeric antigen receptor T (CAR-T) cells as agents against B-cells receptor (BCR), represents a highly targeted and potentially optimal treatment approach. This study summarizes current knowledge about the role of the BAFF\/APRIL system in lymphocyte activation mechanisms, particularly in GN. It also discusses existing biological treatments and explores future directions for drug development based on the CAR-T cell technology.<\/jats:p>","DOI":"10.2478\/aite-2025-0018","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T15:22:12Z","timestamp":1749136932000},"source":"Crossref","is-referenced-by-count":9,"title":["The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies"],"prefix":"10.2478","volume":"73","author":[{"given":"Barbara","family":"Moszczuk","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology , Medical University of Warsaw , Warsaw , Poland"},{"name":"Department of Transplantology, Immunology, Nephrology and Internal Diseases , Medical University of Warsaw , Warsaw , Poland"},{"name":"ProMix Center (ProteogenOmix in Medicine), Department of Clinical Immunology , Medical University of Warsaw , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Mucha","sequence":"additional","affiliation":[{"name":"Department of Transplantology, Immunology, Nephrology and Internal Diseases , Medical University of Warsaw , Warsaw , Poland"},{"name":"ProMix Center (ProteogenOmix in Medicine), Department of Clinical Immunology , Medical University of Warsaw , Warsaw , Poland"},{"name":"Institute of Biochemistry and Biophysics, Polish Academy of Sciences , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3\u017ca","family":"Kucharczyk","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Biophysics, Polish Academy of Sciences , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Zago\u017cd\u017con","sequence":"additional","affiliation":[{"name":"ProMix Center (ProteogenOmix in Medicine), Department of Clinical Immunology , Medical University of Warsaw , Warsaw , Poland"},{"name":"Institute of Biochemistry and Biophysics, Polish Academy of Sciences , Warsaw , Poland"},{"name":"Laboratory of Cellular and Genetic Therapies, Center for Preclinical Research , Medical University of Warsaw , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2026053122152071806_j_aite-2025-0018_ref_001","doi-asserted-by":"crossref","unstructured":"Barratt J, Kim SG, Agha I et al. (2023) WNC 23-1175 updated interim results of a phase 1\/2 study of bion-1301 in patients with IgA nephropathy. Kidney Int Rep 8:S280\u2013S281. https:\/\/doi.org\/10.1016\/j.ekir.2023.02.632","DOI":"10.1016\/j.ekir.2023.02.632"},{"key":"2026053122152071806_j_aite-2025-0018_ref_002","doi-asserted-by":"crossref","unstructured":"Benson MJ, Dillon SR, Castigli E et al. (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180:3655\u20133659. https:\/\/doi.org\/10.4049\/jimmunol.180.6.3655","DOI":"10.4049\/jimmunol.180.6.3655"},{"key":"2026053122152071806_j_aite-2025-0018_ref_003","unstructured":"Bosello S, Youinou P, Daridon C et al. (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35:1256\u20131264."},{"key":"2026053122152071806_j_aite-2025-0018_ref_004","doi-asserted-by":"crossref","unstructured":"Bowman SJ, Fox R, D\u00f6rner T et al. (2022) Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399:161\u2013171. https:\/\/doi.org\/10.1016\/S0140-6736(21)02251-0","DOI":"10.1016\/S0140-6736(21)02251-0"},{"key":"2026053122152071806_j_aite-2025-0018_ref_005","doi-asserted-by":"crossref","unstructured":"Cai J, Gao D, Liu D et al. (2023) Telitacicept for autoimmune nephropathy. Front Immunol 14:1169084. https:\/\/doi.org\/10.3389\/FIMMU.2023.1169084","DOI":"10.3389\/fimmu.2023.1169084"},{"key":"2026053122152071806_j_aite-2025-0018_ref_006","doi-asserted-by":"crossref","unstructured":"Cao Y, Lu G, Chen X et al. (2020) BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6\/NF \u03baB signaling pathway in glomerular mesangial cells. Mol Med Rep 21:795\u2013805. https:\/\/doi.org\/10.3892\/MMR.2019.10870","DOI":"10.3892\/mmr.2019.10870"},{"key":"2026053122152071806_j_aite-2025-0018_ref_007","doi-asserted-by":"crossref","unstructured":"Caza TN, Storey AJ, Hassen SI et al. (2023) Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int 103:593\u2013606. https:\/\/doi.org\/10.1016\/j.kint.2023.01.001","DOI":"10.1016\/j.kint.2023.01.001"},{"key":"2026053122152071806_j_aite-2025-0018_ref_008","doi-asserted-by":"crossref","unstructured":"Chan J, Walters GD, Puri P et al. (2023) Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatol 7:37. https:\/\/doi.org\/10.1186\/S41927-023-00358-3","DOI":"10.1186\/s41927-023-00358-3"},{"key":"2026053122152071806_j_aite-2025-0018_ref_009","doi-asserted-by":"crossref","unstructured":"Cheung CK, Barratt J, Liew A et al. (2024) The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol 3:1346769. https:\/\/doi.org\/10.3389\/FNEPH.2023.1346769","DOI":"10.3389\/fneph.2023.1346769"},{"key":"2026053122152071806_j_aite-2025-0018_ref_010","doi-asserted-by":"crossref","unstructured":"Currie EG, Coburn B, Porfilio EA et al. (2022) Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses. JCI Insight 7:e141289. https:\/\/doi.org\/10.1172\/jci.insight.141289","DOI":"10.1172\/jci.insight.141289"},{"key":"2026053122152071806_j_aite-2025-0018_ref_011","doi-asserted-by":"crossref","unstructured":"Evans LS, Lewis KE, DeMonte D et al. (2023) Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases. Arthritis Rheumatol 75:1187\u20131202. https:\/\/doi.org\/10.1002\/art.42462","DOI":"10.1002\/art.42462"},{"key":"2026053122152071806_j_aite-2025-0018_ref_012","doi-asserted-by":"crossref","unstructured":"Feng J, HU Y, Chang AH et al. (2023) CD19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus \u2013 safety and preliminary efficacy data from a phase I clinical study. Blood 142:4835. https:\/\/doi.org\/10.1182\/blood-2023-186669","DOI":"10.1182\/blood-2023-186669"},{"key":"2026053122152071806_j_aite-2025-0018_ref_013","doi-asserted-by":"crossref","unstructured":"Figgett WA, Deliyanti D, Fairfax KA et al. (2015) Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. J Autoimmun 61:9\u201316. https:\/\/doi.org\/10.1016\/j.jaut.2015.04.007","DOI":"10.1016\/j.jaut.2015.04.007"},{"key":"2026053122152071806_j_aite-2025-0018_ref_014","doi-asserted-by":"crossref","unstructured":"Forero-Delgadillo J, Ochoa V, Restrepo JM et al. (2022) B-cell activating factor (BAFF) and its receptors' expression in pediatric nephrotic syndrome is associated with worse prognosis. PLoS One 17:e0277800. https:\/\/doi.org\/10.1371\/journal.pone.0277800","DOI":"10.1371\/journal.pone.0277800"},{"key":"2026053122152071806_j_aite-2025-0018_ref_015","doi-asserted-by":"crossref","unstructured":"Furie RA, Aroca G, Cascino MD et al. (2022a) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100\u2013107. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920","DOI":"10.1136\/annrheumdis-2021-220920"},{"key":"2026053122152071806_j_aite-2025-0018_ref_016","doi-asserted-by":"crossref","unstructured":"Furie R, Petri M, Zamani O et al. (2011) A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Reum 63:3918\u20133930. https:\/\/doi.org\/10.1002\/ART.30613","DOI":"10.1002\/art.30613"},{"key":"2026053122152071806_j_aite-2025-0018_ref_017","doi-asserted-by":"crossref","unstructured":"Furie R, Rovin BH, Houssiau F et al. (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","DOI":"10.1056\/NEJMoa2001180"},{"key":"2026053122152071806_j_aite-2025-0018_ref_018","doi-asserted-by":"crossref","unstructured":"Furie R, Rovin BH, Houssiau F et al. (2022b) Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol 17:1620\u20131630. https:\/\/doi.org\/10.2215\/CJN.02520322","DOI":"10.2215\/CJN.02520322"},{"key":"2026053122152071806_j_aite-2025-0018_ref_019","doi-asserted-by":"crossref","unstructured":"Furie RA, Rovin BH, Garg JP et al. (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392:1471\u20131483. https:\/\/doi.org\/10.1056\/NEJMoa2410965","DOI":"10.1056\/NEJMoa2410965"},{"key":"2026053122152071806_j_aite-2025-0018_ref_020","doi-asserted-by":"crossref","unstructured":"Gabay C, Krenn V, Bosshard C et al. (2009) Synovial tissues concentrate secreted APRIL. Arthritis Res Ther 11:R144. https:\/\/doi.org\/10.1186\/ar2817","DOI":"10.1186\/ar2817"},{"key":"2026053122152071806_j_aite-2025-0018_ref_021","doi-asserted-by":"crossref","unstructured":"Gordon C, Bassi R, Chang P et al. (2019) Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatol Adv Pract 3:rkz021. https:\/\/doi.org\/10.1093\/rap\/rkz021","DOI":"10.1093\/rap\/rkz021"},{"key":"2026053122152071806_j_aite-2025-0018_ref_022","doi-asserted-by":"crossref","unstructured":"Groom JR, Fletcher CA, Walters SN et al. (2007) BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204:1959\u20131971. https:\/\/doi.org\/10.1084\/jem.20062567","DOI":"10.1084\/jem.20062567"},{"key":"2026053122152071806_j_aite-2025-0018_ref_023","doi-asserted-by":"crossref","unstructured":"Han SS, Yang SH, Jo HA et al. (2018) BAFF and APRIL expression as an autoimmune signature of membranous nephropathy. Oncotarget 9:3292\u20133302. https:\/\/doi.org\/10.18632\/Oncotarget.23232","DOI":"10.18632\/oncotarget.23232"},{"key":"2026053122152071806_j_aite-2025-0018_ref_024","doi-asserted-by":"crossref","unstructured":"Huang SP, Snedecor SJ, Nanji S et al. (2022) Real-world effectiveness of belimumab in systemic lupus erythematosus: A systematic literature review. Rheumatol Ther 9:975\u2013991. https:\/\/doi.org\/10.1007\/S40744-022-00454-9","DOI":"10.1007\/s40744-022-00454-9"},{"key":"2026053122152071806_j_aite-2025-0018_ref_025","doi-asserted-by":"crossref","unstructured":"Huard B, Tran NL, Benkhoucha M et al. (2012) Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One 7:e31837. https:\/\/doi.org\/10.1371\/journal.pone.0031837","DOI":"10.1371\/journal.pone.0031837"},{"key":"2026053122152071806_j_aite-2025-0018_ref_026","doi-asserted-by":"crossref","unstructured":"Jacob CO, Yu N, Sindhava V et al. (2015) Differential development of systemic lupus erythematosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors. Arthritis Rheumatol 67:2523\u20132535. https:\/\/doi.org\/10.1002\/art.39210","DOI":"10.1002\/art.39210"},{"key":"2026053122152071806_j_aite-2025-0018_ref_027","doi-asserted-by":"crossref","unstructured":"Jin HZ, Cai ML, Wang X et al. (2025) Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study. Clin Rheumatol 44:247\u2013256. https:\/\/doi.org\/10.1007\/s10067-024-07266-y","DOI":"10.1007\/s10067-024-07266-y"},{"key":"2026053122152071806_j_aite-2025-0018_ref_028","doi-asserted-by":"crossref","unstructured":"Khare SD, Sarosi I, Xia XZ et al. (2000) Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97:3370\u20133375. https:\/\/doi.org\/10.1073\/pnas.97.7.3370","DOI":"10.1073\/pnas.97.7.3370"},{"key":"2026053122152071806_j_aite-2025-0018_ref_029","doi-asserted-by":"crossref","unstructured":"Kiryluk K, Li Y, Scolari F et al. (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187\u20131196. https:\/\/doi.org\/10.1038\/ng.3118","DOI":"10.1038\/ng.3118"},{"key":"2026053122152071806_j_aite-2025-0018_ref_030","doi-asserted-by":"crossref","unstructured":"Kiyama K, Kawabata D, Hosono Y et al. (2012) Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Res Ther 14:R86. https:\/\/doi.org\/10.1186\/ar3810","DOI":"10.1186\/ar3810"},{"key":"2026053122152071806_j_aite-2025-0018_ref_031","doi-asserted-by":"crossref","unstructured":"Lafayette R, Barbour S, Israni R et al. (2024) A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int 105:1306\u20131315. https:\/\/doi.org\/10.1016\/j.kint.2024.03.012","DOI":"10.1016\/j.kint.2024.03.012"},{"key":"2026053122152071806_j_aite-2025-0018_ref_032","doi-asserted-by":"crossref","unstructured":"Lafayette RA, Canetta PA, Rovin BH et al. (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306\u20131313. https:\/\/doi.org\/10.1681\/asn.2016060640","DOI":"10.1681\/ASN.2016060640"},{"key":"2026053122152071806_j_aite-2025-0018_ref_033","doi-asserted-by":"crossref","unstructured":"Li Z, Chen P, Zhang Y et al. (2024) Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy. Ren Fail 46:2391069. https:\/\/doi.org\/10.1080\/0886022X.2024.2391069","DOI":"10.1080\/0886022X.2024.2391069"},{"key":"2026053122152071806_j_aite-2025-0018_ref_034","doi-asserted-by":"crossref","unstructured":"Luo Y, Qie Y, Gadd ME et al. (2023) Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies. Cancer Immunol Immunother 72:4031\u20134047. https:\/\/doi.org\/10.1007\/S00262-023-03537-w","DOI":"10.1007\/s00262-023-03537-w"},{"key":"2026053122152071806_j_aite-2025-0018_ref_035","doi-asserted-by":"crossref","unstructured":"Lv J, Liu L, Hao C et al. (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014","DOI":"10.1016\/j.ekir.2022.12.014"},{"key":"2026053122152071806_j_aite-2025-0018_ref_036","doi-asserted-by":"crossref","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D et al. (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28:2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","DOI":"10.1038\/s41591-022-02017-5"},{"key":"2026053122152071806_j_aite-2025-0018_ref_037","doi-asserted-by":"crossref","unstructured":"Mar\u00edn-Rosales M, Palafox-S\u00e1nchez CA, Franco-Topete RA et al. (2022) Renal tissue expression of BAFF and BAFF receptors is associated with proliferative lupus nephritis. J Clin Med 12:71. https:\/\/doi.org\/10.3390\/jcm12010071","DOI":"10.3390\/jcm12010071"},{"key":"2026053122152071806_j_aite-2025-0018_ref_038","doi-asserted-by":"crossref","unstructured":"Mathur M, Barratt J, Chacko B et al. (2024) A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. New Engl J Med 390:20\u201331. https:\/\/doi.org\/10.1056\/NEJMOA2305635","DOI":"10.1056\/NEJMoa2305635"},{"key":"2026053122152071806_j_aite-2025-0018_ref_039","doi-asserted-by":"crossref","unstructured":"Mathur M, Chan TM, Oh KH et al. (2023) A PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin a nephropathy: a review of the evidence. J Clin Med 12:6927. https:\/\/doi.org\/10.3390\/jcm12216927","DOI":"10.3390\/jcm12216927"},{"key":"2026053122152071806_j_aite-2025-0018_ref_040","doi-asserted-by":"crossref","unstructured":"McCarthy DD, Kujawa J, Wilson C et al. (2011) Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 121:3991\u20134002. https:\/\/doi.org\/10.1172\/JCI45563","DOI":"10.1172\/JCI45563"},{"key":"2026053122152071806_j_aite-2025-0018_ref_041","doi-asserted-by":"crossref","unstructured":"Mo S, Li Y, He J et al. (2024) Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis. Front Med 11:1472019. https:\/\/doi.org\/10.3389\/fmed.2024.1472019","DOI":"10.3389\/fmed.2024.1472019"},{"key":"2026053122152071806_j_aite-2025-0018_ref_042","doi-asserted-by":"crossref","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S et al. (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385:567\u2013569. https:\/\/doi.org\/10.1056\/NEJMc2107725","DOI":"10.1056\/NEJMc2107725"},{"key":"2026053122152071806_j_aite-2025-0018_ref_043","doi-asserted-by":"crossref","unstructured":"Mucha K, Pac M, P\u0105czek L (2023) Omics are getting us closer to understanding IgA nephropathy. Arch Immunol Ther Exp 71:12. https:\/\/doi.org\/10.1007\/S00005-023-00677-w","DOI":"10.1007\/s00005-023-00677-w"},{"key":"2026053122152071806_j_aite-2025-0018_ref_044","doi-asserted-by":"crossref","unstructured":"Nawata A, Nakayamada S, Hisano S et al. (2023) Original research: differential expression of IFN-\u03b1, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis. Lupus Sci Med 10:e000962. https:\/\/doi.org\/10.1136\/lupus-2023-000962","DOI":"10.1136\/lupus-2023-000962"},{"key":"2026053122152071806_j_aite-2025-0018_ref_045","doi-asserted-by":"crossref","unstructured":"Netti GS, Infante B, Spadaccino F et al. (2019) Serum levels of BAFF and APRIL predict clinical response in anti-PLA2R-positive primary membranous nephropathy. J Immunol Res 2019:8483650. https:\/\/doi.org\/10.1155\/2019\/8483650","DOI":"10.1155\/2019\/8483650"},{"key":"2026053122152071806_j_aite-2025-0018_ref_046","doi-asserted-by":"crossref","unstructured":"Neusser MA, Lindenmeyer MT, Edenhofer I et al. (2011) Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 24:98\u2013107. https:\/\/doi.org\/10.1038\/modpathol.2010.184","DOI":"10.1038\/modpathol.2010.184"},{"key":"2026053122152071806_j_aite-2025-0018_ref_047","doi-asserted-by":"crossref","unstructured":"Oniszczuk J, Beldi-Ferchiou A, Audureau E et al. (2021) Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrol Dial Transplant 36:609\u2013617. https:\/\/doi.org\/10.1093\/ndt\/gfaa279","DOI":"10.1093\/ndt\/gfaa279"},{"key":"2026053122152071806_j_aite-2025-0018_ref_048","doi-asserted-by":"crossref","unstructured":"Petrou D, Kalogeropoulos P, Liapis G et al. (2023) IgA nephropathy: current treatment and new insights. Antibodies 12:40. https:\/\/doi.org\/10.3390\/antib12020040","DOI":"10.3390\/antib12020040"},{"key":"2026053122152071806_j_aite-2025-0018_ref_049","doi-asserted-by":"crossref","unstructured":"Piantoni S, Korsten P (2022) Rituximab-a B cell targeted therapy in systemic lupus erythematosus: where do we stand? Rheumatology 61:1752\u20131755. https:\/\/doi.org\/10.1093\/rheumatology\/keac095","DOI":"10.1093\/rheumatology\/keac095"},{"key":"2026053122152071806_j_aite-2025-0018_ref_050","doi-asserted-by":"crossref","unstructured":"Roos I, Hughes S, McDonnell G et al. (2023) Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis. JAMA Neurol 80:789\u2013797. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1625","DOI":"10.1001\/jamaneurol.2023.1625"},{"key":"2026053122152071806_j_aite-2025-0018_ref_051","doi-asserted-by":"crossref","unstructured":"Sallustio F, Curci C, Chaoul N et al. (2021) High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients. Nephrol Dial Transplant 36:452\u2013464. https:\/\/doi.org\/10.1093\/ndt\/gfaa264","DOI":"10.1093\/ndt\/gfaa264"},{"key":"2026053122152071806_j_aite-2025-0018_ref_052","doi-asserted-by":"crossref","unstructured":"Samy E, Wax S, Huard B et al. (2017) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol 36:3\u201319. https:\/\/doi.org\/10.1080\/08830185.2016.1276903","DOI":"10.1080\/08830185.2016.1276903"},{"key":"2026053122152071806_j_aite-2025-0018_ref_053","doi-asserted-by":"crossref","unstructured":"Selvaskandan H, Barratt J, Cheung CK (2023) Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep 9:203\u2013213. https:\/\/doi.org\/10.1016\/j.ekir.2023.11.026","DOI":"10.1016\/j.ekir.2023.11.026"},{"key":"2026053122152071806_j_aite-2025-0018_ref_054","doi-asserted-by":"crossref","unstructured":"Suzuki H, Kiryluk K, Novak J et al. (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795\u20131803. https:\/\/doi.org\/10.1681\/asn.2011050464","DOI":"10.1681\/ASN.2011050464"},{"key":"2026053122152071806_j_aite-2025-0018_ref_055","doi-asserted-by":"crossref","unstructured":"Trimarchi H, Barratt J, Radhakrishnan J et al. (2024) WCN24-1837 beyond: a phase 3, randomized, double-blind, placebo controlled trial of zigakibart in adults with IgA nephropathy. Kidney Int Rep 9:S177. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.362","DOI":"10.1016\/j.ekir.2024.02.362"},{"key":"2026053122152071806_j_aite-2025-0018_ref_056","unstructured":"Union Register of Medicinal Products \u2013 Public Health \u2013 European Commission. (2024) Union register of medicinal products for human use. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h067.htm. Accessed 25 November 2024."},{"key":"2026053122152071806_j_aite-2025-0018_ref_057","doi-asserted-by":"crossref","unstructured":"Vosters JL, Roescher N, Polling EJ et al. (2012) The expression of APRIL in Sj\u00f6gren's syndrome: aberrant expression of APRIL in the salivary gland. Rheumatology (Oxford) 51:1557\u20131562. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KES080","DOI":"10.1093\/rheumatology\/kes080"},{"key":"2026053122152071806_j_aite-2025-0018_ref_058","doi-asserted-by":"crossref","unstructured":"Wallace DJ, Isenberg DA, Morand EF et al. (2021) Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology 60:5379\u20135389. https:\/\/doi.org\/10.1093\/rheumatology\/keab115","DOI":"10.1093\/rheumatology\/keab115"},{"key":"2026053122152071806_j_aite-2025-0018_ref_059","doi-asserted-by":"crossref","unstructured":"Wang W, He S, Zhang W et al. (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83:1304\u20131314. https:\/\/doi.org\/10.1136\/ARD-2024-225785","DOI":"10.1136\/ard-2024-225785"},{"key":"2026053122152071806_j_aite-2025-0018_ref_060","doi-asserted-by":"crossref","unstructured":"Wang X, Dong Z, Awuah D et al. (2022) CD19\/BAFF-R dual-targeted CAR T cells for treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. Leukemia 36:1015\u20131024. https:\/\/doi.org\/10.1038\/S41375-021-01477-X","DOI":"10.1038\/s41375-021-01477-x"},{"key":"2026053122152071806_j_aite-2025-0018_ref_061","doi-asserted-by":"crossref","unstructured":"Wong DP, Roy NK, Zhang K et al. (2022) A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 13:217. https:\/\/doi.org\/10.1038\/s41467-021-27853-w","DOI":"10.1038\/s41467-021-27853-w"},{"key":"2026053122152071806_j_aite-2025-0018_ref_062","doi-asserted-by":"crossref","unstructured":"Worley K, Milligan S, Rubin B (2023) Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data. Lupus Sci Med 10:e001024. https:\/\/doi.org\/10.1136\/LUPUS-2023-001024","DOI":"10.1136\/lupus-2023-001024"},{"key":"2026053122152071806_j_aite-2025-0018_ref_063","doi-asserted-by":"crossref","unstructured":"Xiao X, Huang S, Chen S et al. (2021) Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res 40:367. https:\/\/doi.org\/10.1186\/S13046-021-02148-6","DOI":"10.1186\/s13046-021-02148-6"},{"key":"2026053122152071806_j_aite-2025-0018_ref_064","doi-asserted-by":"crossref","unstructured":"Xin G, Shi W, Xu LX et al. (2013) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26:683\u2013690. https:\/\/doi.org\/10.5301\/JN.5000218","DOI":"10.5301\/jn.5000218"},{"key":"2026053122152071806_j_aite-2025-0018_ref_065","doi-asserted-by":"crossref","unstructured":"Yu XQ, Li M, Zhang H et al. (2011) A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 44:178\u2013182. https:\/\/doi.org\/10.1038\/NG.1047","DOI":"10.1038\/ng.1047"},{"key":"2026053122152071806_j_aite-2025-0018_ref_066","doi-asserted-by":"crossref","unstructured":"Zhai YL, Zhu L, Shi SF et al. (2016) Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine (Baltimore) 95:e3099. https:\/\/doi.org\/10.1097\/MD.0000000000003099","DOI":"10.1097\/MD.0000000000003099"},{"key":"2026053122152071806_j_aite-2025-0018_ref_067","doi-asserted-by":"crossref","unstructured":"Zhang L, Jin H, Wang D et al. (2023) Case report: successful treatment of refractory membranous nephropathy with telitacicept. Front Immunol 14:1268929. https:\/\/doi.org\/10.3389\/fimmu.2023.1268929","DOI":"10.3389\/fimmu.2023.1268929"},{"key":"2026053122152071806_j_aite-2025-0018_ref_068","doi-asserted-by":"crossref","unstructured":"Zheng N, Wang D, Ming H et al. (2015) BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R. BMC Nephrol 16:72. https:\/\/doi.org\/10.1186\/S12882-015-0064-y","DOI":"10.1186\/s12882-015-0064-y"},{"key":"2026053122152071806_j_aite-2025-0018_ref_069","doi-asserted-by":"crossref","unstructured":"Zhuang Y, Lu H, Li J (2023) Advances in the treatment of IgA nephropathy with biological agents. Chronic Dis Transl Med 10:1\u201311. https:\/\/doi.org\/10.1002\/CDT3.104","DOI":"10.1002\/cdt3.104"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/aite-2025-0018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T22:15:32Z","timestamp":1780265732000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/aite-2025-0018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["10.2478\/aite-2025-0018"],"URL":"https:\/\/doi.org\/10.2478\/aite-2025-0018","relation":{},"ISSN":["1661-4917"],"issn-type":[{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"20250018"}}